ImmunoGen (NASDAQ:IMGN) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), Morningstar.com reports. The company had revenue of $39.40 million during the quarter, compared to analyst estimates of $39.62 million. The firm’s revenue was up 185.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.39) EPS.

Shares of ImmunoGen (NASDAQ:IMGN) opened at $8.91 on Friday. ImmunoGen has a 52-week low of $2.31 and a 52-week high of $10.04. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03.

IMGN has been the topic of a number of research reports. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Tuesday, October 31st. Cantor Fitzgerald restated a “hold” rating and set a $5.00 price objective on shares of ImmunoGen in a research report on Friday, November 3rd. BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. HC Wainwright initiated coverage on ImmunoGen in a research report on Wednesday, January 31st. They set a “buy” rating on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and set a $12.00 price objective on shares of ImmunoGen in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $7.83.

A number of hedge funds have recently modified their holdings of IMGN. FMR LLC grew its position in shares of ImmunoGen by 598.9% in the 2nd quarter. FMR LLC now owns 5,605,285 shares of the biotechnology company’s stock valued at $39,854,000 after buying an additional 4,803,256 shares during the last quarter. BlackRock Inc. grew its position in shares of ImmunoGen by 54.7% in the 4th quarter. BlackRock Inc. now owns 8,470,097 shares of the biotechnology company’s stock valued at $54,294,000 after buying an additional 2,996,116 shares during the last quarter. State Street Corp grew its position in shares of ImmunoGen by 159.1% in the 2nd quarter. State Street Corp now owns 4,141,583 shares of the biotechnology company’s stock valued at $29,450,000 after buying an additional 2,542,876 shares during the last quarter. Chicago Equity Partners LLC grew its position in shares of ImmunoGen by 124.7% in the 3rd quarter. Chicago Equity Partners LLC now owns 490,635 shares of the biotechnology company’s stock valued at $3,753,000 after buying an additional 272,315 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of ImmunoGen in the 3rd quarter valued at about $1,780,000. Institutional investors and hedge funds own 67.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ImmunoGen (IMGN) Releases Earnings Results, Misses Estimates By $0.03 EPS” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://theolympiareport.com/2018/02/11/immunogen-imgn-releases-earnings-results-misses-estimates-by-0-03-eps.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Earnings History for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.